Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Cyclophosphamide

Review the clinical trials studying cyclophosphamide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 301-325 of 420

JV-213 Autologous CD79b-Targeting CAR-T Cell Therapy in Treating Adults with Relapsed or Refractory B-Cell Lymphomas
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
CS1-CAR T Therapy following Chemotherapy in Treating Patients with Relapsed or Refractory CS1 Positive Multiple Myeloma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Genetically Engineered Cells (CART-EGFR-IL13Ra2 Cells) with Lymphodepleting Chemotherapy or Prior to Surgical Resection in Patients with Recurrent Wild-type EGFR Amplified IDH-Wildtype Glioblastoma
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Cellular Therapy (GPC2-CAR T-Cells) for the Treatment of Children and Young Adults with Relapsed or Refractory Medulloblastoma and other Central Nervous System Embryonal Tumors
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Recurrent or Refractory B Cell Lymphomas
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells with Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Patients with Relapsed or Refractory B-cell Hematologic Malignancies
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
iC9-CAR.CSPG4 T-Cells for the Treatment of Patients with Recurrent or Refractory Head and Neck Squamous Cell Carcinoma
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
CD45RA Depleted T Cell Infusion after Alpha/Beta Depleted Stem Cell Transplant for the Reduction of Complications in Patients at Risk for Viral or Fungal Infections
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Autologous B7-H3 Chimeric Antigen Receptor T Cells for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Central Nervous System Lymphoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
CRISPR Delivered Anti-BCMA Chimeric Antigen Receptor T Cells (1XX BCMA CAR-T cells) for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Active
Location: University of California San Francisco, San Francisco, California
Hypofractionated Radiation and Lymphodepleting Chemotherapy Followed by B7-H3-CAR T Cells for the Treatment of Pediatric Patients with Relapsed or Refractory Sarcomas
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
A Lymphodepleting Combination of Total Body Irradiation and Cyclophosphamide before CAR T-Cell Therapy (Cilta-Cel) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Poor Kidney Function
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
TROP2-CAR-NK cells in Combination with Cetuximab for the Treatment of Colorectal Cancer in Patients with Minimal Residual Disease
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Axicabtagene Ciloleucel Reinfusion for the Treatment of Relapsed and/or Refractory High-Risk Non-Hodgkin Lymphoma
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Genetically Engineered Cells (UCD19 CAR T Cells) for the Treatment of B Acute Lymphoblastic Leukemia Patients with Minimal Residual Disease at First Complete Remission
Status: Active
Location: UCHealth University of Colorado Hospital, Aurora, Colorado
huCART19-IL18 Cells for the Treatment of Relapsed or Refractory CD19+ Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Acute Lymphoblastic Leukemia
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Genetically Engineered Cells (TGFβR-2 KO CD70 CAR NK Cell Therapy) with Lymphodepleting Chemotherapy for the Treatment of Unresectable or Metastatic Refractory Clear Cell Renal Cell Carcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
PHOX2B Peptide-Centric Chimeric Antigen Receptor Autologous T cells for the Treatment of Relapsed or Refractory Neuroblastoma
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
CAR T-cell Therapy (CD70-CAR) for the Treatment of Hematological Malignancies in Pediatric Patients
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Chimeric Antigen Receptor (CAR) T-cell Therapy with iC9-CAR.B7-H3 T cells for the Treatment of Patients with Recurrent Platinum Resistant or Refractory Epithelial Ovarian Cancer
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Chimeric Antigen Receptor (CAR) T-cell Therapy with iC9-CAR.B7-H3 T-cells for the Treatment of Refractory Pancreatic Ductal Adenocarcinoma
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
TROP2-CAR-NK for the Treatment of Patients with Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Genetically Engineered Cells (TmPSMA-02 CAR T Cells) for the Treatment of Patients with Metastatic Castrate-Resistant Prostate Cancer
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania